JP2024545441A5 - - Google Patents

Info

Publication number
JP2024545441A5
JP2024545441A5 JP2024533245A JP2024533245A JP2024545441A5 JP 2024545441 A5 JP2024545441 A5 JP 2024545441A5 JP 2024533245 A JP2024533245 A JP 2024533245A JP 2024533245 A JP2024533245 A JP 2024533245A JP 2024545441 A5 JP2024545441 A5 JP 2024545441A5
Authority
JP
Japan
Prior art keywords
closely related
composition according
species
sequence
related species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024533245A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024545441A (ja
Filing date
Publication date
Priority claimed from NL2030011A external-priority patent/NL2030011B1/en
Application filed filed Critical
Publication of JP2024545441A publication Critical patent/JP2024545441A/ja
Publication of JP2024545441A5 publication Critical patent/JP2024545441A5/ja
Pending legal-status Critical Current

Links

JP2024533245A 2021-12-03 2022-11-30 脂肪肝の予防、及び治療 Pending JP2024545441A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2030011 2021-12-03
NL2030011A NL2030011B1 (en) 2021-12-03 2021-12-03 Prevention or treatment of hepatic steatosis
PCT/EP2022/083885 WO2023099579A1 (en) 2021-12-03 2022-11-30 Prevention or treatment of hepatic steatosis

Publications (2)

Publication Number Publication Date
JP2024545441A JP2024545441A (ja) 2024-12-06
JP2024545441A5 true JP2024545441A5 (enExample) 2025-12-10

Family

ID=80448857

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024533245A Pending JP2024545441A (ja) 2021-12-03 2022-11-30 脂肪肝の予防、及び治療

Country Status (7)

Country Link
US (1) US20250025517A1 (enExample)
EP (1) EP4440588A1 (enExample)
JP (1) JP2024545441A (enExample)
CN (1) CN118660712A (enExample)
NL (1) NL2030011B1 (enExample)
TW (1) TW202332457A (enExample)
WO (1) WO2023099579A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025077370A1 (zh) * 2023-10-12 2025-04-17 雷文虎克生物技术股份有限公司 艾克曼嗜黏蛋白菌及其用于预防非酒精性脂肪肝炎的用途
WO2025229145A1 (en) 2024-05-02 2025-11-06 Stichting Amsterdam UMC Desulfovibrio piger species for prevention or treatment of hepatic steatosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3140096A1 (en) * 2019-05-21 2020-11-26 Pendulum Therapeutics, Inc. Methods and compositions for treating liver disorders
WO2021204719A1 (en) 2020-04-07 2021-10-14 Wholefiber Holding B.V. Particles comprising inulin for use as medicament or supplement

Similar Documents

Publication Publication Date Title
Abatenh et al. Health benefits of probiotics
Parvez et al. Probiotics and their fermented food products are beneficial for health
Fooks et al. Probiotics as modulators of the gut flora
Kalantzopoulos Fermented products with probiotic qualities
Holzapfel et al. Introduction to pre-and probiotics
Saxelin et al. Probiotic and other functional microbes: from markets to mechanisms
CA2837479C (en) Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
Rabot et al. Guidance for substantiating the evidence for beneficial effects of probiotics: impact of probiotics on digestive system metabolism
TWI594758B (zh) 包含雙歧桿菌的組合物、其製備方法及其用途
Marteau et al. Probiotics and health: new facts and ideas
RU2011150216A (ru) Детские питательные смеси, содержащие пробиотические микроорганизмы
JP2013507394A5 (enExample)
KR102825170B1 (ko) 프로바이오틱 비피도박테리움 브레베 균주 및 상기 균주를 포함하는 조성물
Putta et al. Probiotics: supplements, food, pharmaceutical industry
JP2009511469A (ja) 脂肪代謝及び肥満に影響を及ぼすプロバイオティクス
JP7126004B2 (ja) 組成物及びその使用
Tomičić et al. Beneficial properties of probiotic yeast Saccharomyces boulardii
HRP20180053T1 (hr) Novi soj bakterije bifidobacterium animalis subsp. lactis cect 8145 i njegova upotreba u liječenju i/ili sprječavanju prekomjerne težine i pretilosti, te bolesti povezanih s njima
CN111956676A (zh) 一种包含人参提取物和益生菌的微生态制剂及其制备方法和应用
JP2022533672A5 (enExample)
RU2013126609A (ru) Экструдированные нереплицирующиеся пробиотические микроорганизмы и их польза для здоровья
JP2024545441A5 (enExample)
Khatun et al. Emerging role of probiotics in advancement of combating physical abnormalities and diseases: a systematic perspective analysis
Vijaya Kumar et al. Beneficial effects of probiotics and prebiotics on human health
CN120390793A (zh) 黏膜乳杆菌和需要glp-1增加的疾病